Of the variables that were statistically significant in the univariate analysis (Table S3), a 10-year age increase, history of diabetes or CVD, 5 g/L serum albumin decrease, and ESA treatment were significantly associated with higher CV-MACE risk in the joint final model (Table 2). The gene discussed is ALB; the disease is diabetes mellitus.